ArticleFrontiers in endocrinology2026
Metabolomics identifies candidate diagnostic biomarkers for pituitary apoplexy.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pituitary apoplexy is a clinical emergency resulting from hemorrhage or infarction of a pituitary adenoma, which leads to a sudden increase in tumor volume, acute neuroendocrine dysfunction, and local compressive symptoms. In severe cases, it may be life-threatening. The diagnosis of this condition remains challenging, especially in patients without a prior history of pituitary disease, and reliable serum biomarkers are currently lacking. Metabolomics enables the systematic identification of metabolic alterations under physiological and pathological conditions, thereby providing a powerful tool for elucidating disease mechanisms and discovering diagnostic biomarkers. Methods: In this study, untargeted metabolomics analysis using UPLC-MS/MS was performed on serum samples collected from 39 patients with nonapoplectic pituitary adenoma and 11 patients with pituitary apoplexy. Principal component analysis (PCA) and orthogonal partial least squares discriminant analysis (OPLS-DA) were applied to assess differences in metabolic profiles between the two groups. Differential metabolites were identified based on variable importance in projection (VIP > 1) and an independent-samples Results: Compared with the nonapoplectic pituitary adenoma group, the pituitary apoplexy group showed distinct serum metabolic profiles, with 92 metabolites upregulated and 310 metabolites downregulated. Further analysis revealed two key differential metabolites-glycerol-3-phosphate (G-3-P) and Conclusions: This study reveals distinct serum metabolic profiles between the pituitary apoplexy group and the nonapoplectic pituitary adenoma group, offering novel metabolic insights into the pathogenesis of pituitary apoplexy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.